Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G, Andrillon A, Leclercq M, Sève P, Bielefeld P, Gueudry J, Sené T, Titah C, Moulinet T, Rouvière B, Sène D, Desbois AC, Domont F, Touhami S, Thibault T, Chamieh CE, Cacoub P, Kodjikian L, Biard L, Bodaghi B, Saadoun D.
Maalouf G, et al. Among authors: titah c.
Am J Ophthalmol. 2022 Jun;238:173-180. doi: 10.1016/j.ajo.2022.02.002. Epub 2022 Feb 13.
Am J Ophthalmol. 2022.
PMID: 35172172